Emerging treatments
Gastric antisecretory agents
H2 antagonists and proton pump inhibitors may have a role in the treatment of acute pancreatitis by decreasing pancreatic stimulation; however, more research is needed.
CM4620
CM4620, a novel calcium release-activated calcium channel inhibitor for the treatment of acute pancreatitis, has received fast-track designation from the US Food and Drug Administration and orphan designation from the European Medicines Agency. CM4620 is expected to reduce cell damage and death in the pancreas, thereby minimising symptoms.
Use of this content is subject to our disclaimer